NEWS
新闻资讯
2025-01-10
2024.12
Nanolattix T320 Cancer Drug Successfully Receives U.S. FDA Clinical Approval
2025-01-10
2024.11
Nanolattix's Innovative Drug T320 Receives Clinical Trial Approval from Australia's TGA
2025-01-10
2024.9
Nanolattix Submits Dual IND Applications for Cancer Drug T320 in China and the U.S
U.S. FDA Grants Orphan Drug Designation to Nanolattix T320 for Pancreatic Cancer Treatment
10
2025/01
Nanolattix T320-ADC Successfully Selected and Signed as a 'Major Special Project' in Shanxi Province!
10
2025/01
Nanolattix Completes Tens of Millions in Series A Financing
10
2025/01
